
CONCEPTION OF THE STRATEGY ADVANCING BIOPHARMACEUTICAL DEVELOPMENT EUROPE 2024

KNOWLEDGE SHARING AND CAPACITY BUILDING

- Don't overlook the regulatory tools we do have not all tools are available everywhere, and so we all must be change ambassadors.
- The AI-ML applications to be used for control and prediction of manufacturing are *expected to be covered by the PQS* rather than entered in the dossier, similar thoughts about GMP and PACMPS.
- Internal advocacy is as important as external advocacy.

CMC STRATEGY FORUM EUROPE 2024 BY THE NUMBERS



Attendees

75

Participation



Participation

69



Country Collaboration

20

Austria | Belgium | Canada | Denmark | Finland | France | Germany | Ireland | Israel | Italy | Japan | Netherlands | Norway | South Korea | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States

